Variation of oxidative stress parameters in patients with lung, breast and colon cancer

Yıl 2019, Cilt: 16 Sayı: 2, 235 - 240, 29.08.2019

Ömer Faruk Özer , Eray Metin Güler , Şahabettin Selek , Ganime Çoban , Hacı Mehmet Türk Abdurrahim Koçyiğit

https://doi.org/10.35440/hutfd.576016

Cited By: 4

Öz

Background: Cancer is a very common deadly disease in the world. In the cancer
formation oxidative stress on the cellular level is thought to be effective for
many reasons. The aim of this study was to investigate the changes in oxidative
status in cancer types in lung, breast and colon cancers.

Methods:
Forty four lung cancer patients, 37 breast cancer patients and 20 colon cancer
patients in the medical oncology department were included in the study. All
patients were histopathologically diagnosed. Total Antioxidant Levels (TAS),
Total Oxidant Levels (TOS) and Catalase (CAT) and Myeloperoxidase (MPO) enzyme
activities were measured by photometric method in autoanalyser and compared
with 43 healthy volunteers.

Results:
TOS was significantly higher in all cancer types than control group, but not
statistically significant, but significantly higher in breast cancer
(p<0.002). Oxidative Stress Index (OSI) were found to be significantly lower
in all three types of cancer than in the control group (p<0.001). TAS, CAT
and MPO values were significantly higher in all three types of cancer than in
the control group (p<0.001).

Conclusion: In the study, it was concluded that oxidative stress increased in
cancer, but increased oxidative stress may decrease OSI level due to induction
of antioxidant defense system.

 

Keywords:
Oxidative stress, Lung cancer, Breast cancer, Colon cancer

Anahtar Kelimeler

Oxidative stress, Lung cancer, Breast cancer, Colon cancer

Akciğer, meme ve kolon kanserli hastalarda oksidatif stres parametrelerinin değişimi

Öz

Amaç: Kanser dünyada çok yaygın ölümcül bir hastalıktır. Kanser oluşumunda
birçok nedenden dolayı hücresel düzeyde meydana gelen oksidatif stresin etkili
olduğu düşünülmektedir. Bu çalışmada akciğer, meme ve kolon kanserlerinde
oksidatif durumun kanser türlerindeki değişiminin araştırılması amaçlandı.

Materyal ve
Metot: Medikal Onkoloji
bölümünde tedavileri süren 44 akciğer kanseri, 37 meme kanseri, 20 kolon
kanseri hastası çalışmaya dahil edildi. Çalışmaya katılan hastaların tamamı
histopatolojik olarak tanısı kesinleştirilirmiş hastalardı. Hastaların Total
Antioksidan Seviye (TAS), Total Oksidan Seviye (TOS) ile Katalaz (CAT) ve
Myeloperoksidaz (MPO) enzim aktiviteleri otoanalizörde fotometrik yöntemle
ölçülüp, 43 sağlıklı gönüllü ile karşılaştırıldı.

Bulgular: TOS seviyeleri kontrol grubuna göre meme kanserinde anlamlı olarak
yüksek bulunurken (p<0.002), diğer kanser gruplarında yüksek olmakla
birlikte anlamlı fark bulunmadı. 
Oksidatif Stres İndeksi (OSİ) ise her üç kanser türünde de kontrol
grubuna göre anlamlı derecede düşük bulundu (p<0.001). TAS, CAT ve
MPO aktiviteleri her üç kanser tipinde de kontrol grubuna göre anlamlı derecede
yüksek idi. (p<0.001).

Sonuç: Çalışmada, kanserde oksidatif stresin arttığı ancak, artmış oksidatif
stresin antioksidan savunma sistemini indüklemesi nedeni ile OSI seviyesini
düşürmüş olabileceği sonucuna varıldı.

 

Anahtar Kelimeler: Oksidatif stres, Akciğer kanseri, Meme kanseri, Kolon kanseri

Anahtar Kelimeler

Oksidatif stres, Akciğer kanseri, Meme kanseri, Kolon kanseri

Kaynakça

• 1. Minna JD, Roth JA, Gazdar AF. Focus on lung cancer. Cancer cell. 2002;1(1):49-52.
• 2. Yılmaz İ, Akçay MN, Polat MF, Demiryılmaz İ, Biçer Ş. Kolorektal Kanserli Hastalarda Serum Paraoksonaz (PON) Seviyesi. Okmeydanı Tıp Dergisi. 2015;31(2):65-70.
• 3. Çiftçi N. Oksidatif Stresin Kanserdeki Rolü: Antioksidanlar Kanser Progresyonunun Yakıtı Olabilir mi? Ahi Evran Tıp Dergisi. 2017; 1: 8-13.
• 4. Poirier LA. Stages in carcinogenesis: alteration by diet. Am J Clin Nutr 1987;45:185-9.
• 5. Karabulut H, Gülay MŞ. Serbest radikaller. Mehmet Akif Ersoy Üniversitesi Sağlık Bilimleri Enstitüsü Dergisi. 2016;4(1).
• 6. Valko M, Rhodes C, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1-40.
• 7. Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. Int J Biomed Sci. 2008;4(2):89.
• 8. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem. 2006;97(6):1634-58.
• 9. Liou G-Y, Storz P. Reactive oxygen species in cancer. Free Radic Res. 2010;44(5):479-96.
• 10. Brigelius-Flohé R. Tissue-specific functions of individual glutathione peroxidases. Free Radic Biol Med. 1999;27(9-10):951-65.
• 11. Schieber M, Chandel NS. ROS function in redox signaling and oxidative stress. Curr Biol. 2014;24(10):R453-R62.
• 12. Reczek CR, Chandel NS. ROS-dependent signal transduction. Curr Opin Cell Biol. 2015;33:8-13.
• 13. Mittler R. ROS are good. Trends Plant Sci. 2017;22(1):11-9.
• 14. Erel O. A novel automated method to measure total antioxidant response against potent free radical reactions. Clin Biochem. 2004;37(2):112-9.
• 15. Erel O. A new automated colorimetric method for measuring total oxidant status. Clin Biochem. 2005;38(12):1103-11.
• 16. Kavakli HS, Alici O, Koca C, Ilhan A, Isik B. Caffeic acid phenethyl ester decreases oxidative stress index in blunt spinal cord injury in rats. Hong Kong J Emerg Me 2010;17(3):250.
• 17. Aebi HE. Methods of Enzymatic Analysis, H. U. Bergmeyer, ed., Third Edition, VCH, Weinheim, West Germany 1983;3:273.
• 18. Krawisz J, Sharon P, Stenson W. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Gastroenterology. 1984;87(6):1344-50.
• 19. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4(8):118.
• 20. Birben E, Sahiner UM, Sackesen C, Erzurum S, Kalayci O. Oxidative stress and antioxidant defense. World Allergy Organ J. 2012;5(1):9.
• 21. Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85.
• 22. Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931.
• 23. Portakal O, Özkaya Ö, Bozan B, Koşan M, Sayek I. Coenzyme Q10 concentrations and antioxidant status in tissues of breast cancer patients. Clin Biochem. 2000;33(4):279-84.
• 24. Kaynar H, Meral M, Turhan H, Keles M, Celik G, Akcay F. Glutathione peroxidase, glutathione-S-transferase, catalase, xanthine oxidase, Cu-Zn superoxide dismutase activities, total glutathione, nitric oxide, and malondialdehyde levels in erythrocytes of patients with small cell and non-small cell lung cancer. Cancer Lett. 2005;227(2):133-9.
• 25. Schumacker PT. Reactive oxygen species in cancer: a dance with the devil. Cancer Cell. 2015;27(2):156-7.
• 26. Sagai M, Bocci V. Mechanisms of action involved in ozone therapy: is healing induced via a mild oxidative stress? Med Gas Res. 2011;1(1):29.
• 27. Berasain C, Castillo J, Perugorria MJ, Latasa MU, Prieto J, Avila MA. Inflammation and liver cancer: new molecular links. Ann N Y Acad Sci. 2009;1155:206-21.
• 28. Engels EA. Inflammation in the development of lung cancer: epidemiological evidence. Expert Rev Anticancer Ther. 2008;8(4):605-15.
• 29. Ajila V, Ravi V, Kumari S, Babu S, Hegde S, Madiyal A. Serum and salivary myeloperoxidase in oral squamous cell carcinoma: A preliminary study. Clin Cancer Investig J. 2015;4(3):344.
• 30. Lai W-M, Chen C-C, Lee J-H, Chen C-J, Wang J-S, Hou Y-Y, et al. Second primary tumors and myeloperoxidase expression in buccal mucosal squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2013;116(4):464-73.
• 31. Rainis T, Maor I, Lanir A, Shnizer S, Lavy A. Enhanced oxidative stress and leucocyte activation in neoplastic tissues of the colon. Dig Dis Sci. 2007;52(2):526-30.
• 32. Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, et al. Association of myeloperoxidase with ovarian cancer. Tumor Biol. 2014;35(1):141-8.
• 33. Qin X, Deng Y, Zeng Z-Y, Peng Q-L, Huang X-L, Mo C-J, et al. Myeloperoxidase polymorphism, menopausal status, and breast cancer risk: an update meta-analysis. PloS one. 2013;8(8):e72583.
• 34. Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population. Mol Med Rep. 2011;4(1):87-92.